Please Wait
Applying Filters...
Menu
Xls

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/06/06/3095128/0/en/Apellis-and-Sobi-Announce-EMPAVELI-pegcetacoplan-Showed-Sustained-Efficacy-at-One-Year-in-Phase-3-Study-for-C3G-and-Primary-IC-MPGN.html

GLOBENEWSWIRE
06 Jun 2025

https://www.prnewswire.com/news-releases/invitation-sobis-aspaveli---52-week-phase-3-valiant-data-in-nephrology-302471733.html

PR NEWSWIRE
03 Jun 2025

https://www.fiercepharma.com/pharma/apellis-weak-syfovre-quarter-signals-uphill-climb-geographic-atrophy-med-mizuho

FIERCE PHARMA
14 May 2025

https://www.globenewswire.com/news-release/2025/04/01/3053146/0/en/Apellis-Announces-FDA-Acceptance-and-Priority-Review-of-the-Supplemental-New-Drug-Application-for-EMPAVELI-pegcetacoplan-for-C3G-and-Primary-IC-MPGN.html

GLOBENEWSWIRE
01 Apr 2025

https://www.globenewswire.com//news-release/2025/02/20/3029307/0/en/Apellis-and-Sobi-Announce-EMA-Validation-of-Indication-Extension-Application-for-Aspaveli-pegcetacoplan-for-C3G-and-Primary-IC-MPGN.html

GLOBENEWSWIRE
20 Feb 2025

https://www.prnewswire.com/news-releases/ema-validates-indication-extension-application-for-aspaveli-for-treatment-of-c3g-and-primary-ic-mpgn-302381200.html

PR NEWSWIRE
20 Feb 2025